Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 12.24 -0.60 (-4.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Travere Therapeutics Inc < Previous 1 2 3 Next > Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Third Quarter 2023 Financial Results November 07, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 November 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Third Quarter 2023 Financial Results October 24, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 October 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties September 29, 2023 San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc. Via SBWire Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) September 26, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan September 21, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics September 05, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals September 05, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference August 31, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 August 24, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc. August 10, 2023 San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Travere Therapeutics Reports Second Quarter 2023 Financial Results August 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Second Quarter 2023 Financial Results July 20, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics July 17, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals July 17, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 June 08, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences June 01, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria May 31, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports First Quarter 2023 Financial Results May 04, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm May 02, 2023 From The Schall Law Firm Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm May 01, 2023 From The Schall Law Firm Via Business Wire Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis May 01, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report First Quarter 2023 Financial Results April 26, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.